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Abstract
Introduction: Sepsis is thought to be an abnormal inflammatory response to infection. However, most clinical trials
of drugs that modulate the inflammatory response of sepsis have been unsuccessful. Emerging genomic evidence
shows that the host response in sepsis does not conform to a simple hyper-inflammatory/hypo-inflammatory
model. We, therefore, synthesized current genomic studies that examined the host response of circulating
leukocytes to human sepsis.
Methods: Electronic searches were performed in Medline and Embase (1987 to October 2010), supplemented by
additional searches in multiple microarray data repositories. We included studies that (1) used microarray, (2) were
performed in humans and (3) investigated the host response mediated by circulating leukocytes.
Results: We identified 12 cohorts consisting of 784 individuals providing genome-wide expression data in early
and late sepsis. Sepsis elicited an immediate activation of pathogen recognition receptors, accompanied by an
increase in the activities of signal transduction cascades. These changes were consistent across most cohorts.
However, changes in inflammation related genes were highly variable. Established inflammatory markers, such as
tumour necrosis factor-a (TNF-a), interleukin (IL)-1 or interleukin-10, did not show any consistent pattern in their
gene-expression across cohorts. The finding remains the same even after the cohorts were stratified by timing
(early vs. late sepsis), patient groups (paediatric vs. adult patients) or settings (clinical sepsis vs. endotoxemia
model). Neither a distinctive pro/anti-inflammatory phase nor a clear transition from a pro-inflammatory to anti-
inflammatory phase could be observed during sepsis.
Conclusions: Sepsis related inflammatory changes are highly variable on a transcriptional level. We did not find
strong genomic evidence that supports the classic two phase model of sepsis.
Introduction
Sepsis is characterised by a bewildering array of
abnormalities in both innate and adaptive immune sys-
tems. To help explain this complex pathophysiology, a
two-phase model has been used by investigators. This
model postulates that sepsis consists of an initial phase
of systemic inflammatory response syndrome, followed
b yal a t e rp h a s eo fc o m p e n s a t o r ya n t i - i n f l a m m a t o r y
response syndrome. This two-phase model has been the
reigning paradigm under which scientists develop new
therapeutic agents, with new drugs targeting either the
pro-inflammatory or the anti-inflammatory arm of the
host response. However, clinical trials have consistently
failed to demonstrate any survival benefit of drugs that
target the inflammation pathway. As a result, concerns
have been raised regarding the validity of treating sepsis
simply as a pro-inflammatory or anti-inflammatory
phenomenon.
Complicating this uncertainty is the limited evidence
to verify the two-phase model. Cytokine studies have
been the mainstay evidence that provide support for the
inflammation-based model. However, increasingly con-
flicting findings have emerged from recent cytokine stu-
dies [1-3]. Furthermore, it is often difficult to determine
the exact nature of the host response (for example, pro-
inflammatory versus anti-inflammatory) on the basis of
cytokine measurement alone, which is highly variable
depending on the choice of the cytokine used and the
timing of the measurements.
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assessed the validity of the inflammation-based model
using transcriptional level data. Genome-wide transcrip-
tional studies have recently emerged as a powerful
investigational tool to study complex disease [4]. These
studies avoid the selection bias inherent in most cyto-
kine studies, where only a small number of pre-selected
genes can be examined. In this systematic review, we
synthesized genomic data of recent microarray studies
where the transcriptional changes of circulating leuko-
cytes were examined in both experimental and clinical
sepsis in humans.
Materials and methods
Search strategy and selection criteria
We searched in Medline and Embase, without language
restriction, all publications on gene-expression studies
between January 1987 and October 2010. In 1987 DNA
array technology was first described, hence this year
formed the starting point of our search [5]. We hand-
searched the reference lists of every primary study for
additional publications. Further searches were performed
by reviewing journal editorials and review articles.
The search strategy used the following search terms:
(1) “gene-expression profiling”,( 2 )“microarray analysis”,
(3) “transcription profiling”,( 4 )“cluster analysis”,
(5) “Affymetrix”,( 6 )“GeneChip”,( 7 )“sepsis”,( 8 )“sepsis
syndrome”,( 9 )“septicaemia”,( 1 0 )“bacteraemia”,
(11) “septic shock”, (12) “infection”, (13) “systemic
inflammatory response syndrome”,( 1 4 )“SIRS”,
(15) “systemic inflammation”, (16) “endotoxin”.
We also performed searches in public repositories of
microarray datasets, including the National Centre for
Biotechnology Information (Gene Expression Omnibus),
the European Bioinformatics Institute (ArrayExpress),
and the Centre for Information Biology Gene Expression
Database (CIBEX). Datasets from microarray database
were then cross-referenced with publications retrieved
from Medline and Embase. Only datasets published as
full reports were included in the final analysis.
We included a broad spectrum of gene-expression stu-
dies, including ones that are (1) cross-sectional or longi-
tudinal design, (2) on different microarray platforms,
(3) on whole blood or purified leukocytes, (4) in healthy
volunteers or infected human hosts, and (5) paediatric
or adult patients. As we only sought data on a genome-
wide scale, we have excluded studies that assayed only a
small number of genes, such as (1) Northern blot or
PCR, (2) single gene or individual pathway studies,
(3) proteomic studies, and (4) single-nucleotide poly-
morphism studies. We included custom designed micro-
arrays only if such arrays are designed to study changes
in inflammation pathways. Since we were interested in
host response on a systematic level, as reflected by
circulating leukocytes, we have excluded studies that
(1) focused on resident immun ec e l l ss u c ha sa l v e o l a r
macrophages or lymphoid tissue cells, and (2) used solid
organ tissues such as spleen or liver.
Data extraction
We extracted study level data according to a pre-specified
template, which included participant demographics,
country of origin, clinical setting and inclusion criteria.
A separate template was used to collect details of microar-
ray experiments, including sample collection procedures,
cell separation techniques, target cell types, methods used
to extract ribonucleic acids, cDNA synthesis and hybirdi-
zation, microarray platforms used, number of probe set on
arrays, microarray data processing and normalization
methods. We extracted the signature gene list from each
published report or from the accompanied data file in the
journal websites. Where available, results of functional
analyses were also extracted. These included results of
cluster analyses, principle component analyses or pathway
analyses.
Quality assessment
We performed a quality assessment of each study based
on criteria modified from published guidelines on the
statistical analysis and reporting of microarray data [6].
The assessment was performed using a 14-item checklist
covering three quality domains including data acquisi-
tion (three items), statistical analysis (six items) and vali-
dation of microarray findings (five items).
Data synthesis
We performed a narrative synthesis on genomic data
extracted from each study. First, individual genes from
the gene list of primary studies were manually annotated
by cross-referencing with publicly available gene nomen-
clatures databases (for example, Genebank, Locuslink,
Affymetrix gene identifiers). Where a gene list was not
available, findings on functional analyses reported by the
original authors were used. These included cluster ana-
lysis or gene network analysis performed on the original
microarray data. All results were then collated and pre-
sented in evidence tables. Due to the heterogeneous nat-
ure of the included studies, meta-analysis of the
microarray data was not performed.
Results
The literature search yielded 7,548 citations in electronic
databases and 142 datasets in microarray data reposi-
tories. Of these, 12 patient cohorts met the inclusion cri-
teria and were included in the final analysis (Figure 1).
Clinical characteristics of the included studies are
summarized in Table 1. The cohorts were drawn from a
broad spectrum of clinical settings including hospital
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tres. The majority of the study participants were criti-
cally ill patients diagnosed with sepsis or infection.
Among patients with sepsis, a full range of sepsis
syndrome was represented (for example, sepsis, severe
sepsis and septic shock).
Details of the microarray experiments are summarized
in Tables 2. The target tissue was either whole blood or
Figure 1 Study selection.
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Page 4 of 11Table 1 Summary of studies characteristics
Prucha [14] Tang-1
[15,16]
Ramilo [17] Tang-2 [18] Talwar [8] Payen [19] Cobb
[20,21]
Pachot
[22]
Prabhakar [9] Calvano
[10]
Wong
[23-26]
Johnson
[27,28]
Aims Diagnostic
prediction
Diagnostic
prediction
Diagnostic
prediction
Diagnostic
prediction
Functional
analysis
Prognostic
study
Prognostic
study
Prognostic
study
Functional
analysis
Functional
analysis
Combined
analysis
¥
Functional
analysis
Study
design
Cross-sectional Cross-sectional Cross-sectional Cross-sectional Longitudinal Longitudinal Longitudinal Cross-
sectional
Longitudinal Longitudinal Longitudinal Longitudinal
Country Czech Rep. Australia U.S.A. Australia U.S.A. France U.S.A. France U.S.A. U.S.A. U.S.A. U.S.A.
Total (n) 12 94 148 70 12 17 176 38 12 14 101 90
Mean Age
(yr)
58.9 63.5 3.4 65.5 30 59 35.7 67 (18 to 40)
† (18 to 40)
† 3.2 44
Clinical
setting
Adult ICU Adult ICU Pediatric
wards
Adult ICU University
clinic
Adult ICU Adult ICU Adult ICU University
clinic
University
clinic
Pediatric ICU Trauma ICU
Inclusion
criteria
Severe sepsis Sepsis Acute
infection
Sepsis Healthy
volunteers
Septic shock Post-trauma Septic
shock
Healthy
volunteers
Healthy
volunteers
Sepsis SIRS
Control
group
Surgical
patients
SIRS patients Healthy
subjects
SIRS patients Healthy
subjects
Subjects at
time zero
Non-septic
patients
NA Subjects at
time zero
Healthy
subjects
Non-septic
patients
SIRS patients
SIRS denotes systemic inflammatory response syndrome. ICU denotes intensive care unit. NA denotes not applicable.
†Mean age not available.
¥Both functional analysis and diagnostic prediction.
Table 2 Microarray experiments in included studies
Prucha
[14]
Tang-1
[15,16]
Ramilo
[17]
Tang-2
[18]
Talwar
[8]
Payen
[19]
Cobb
[20,21]
Pachot
[22]
Prabhakar
[9]
Calvano
[10]
Wong
[23-26]
Johnson
[27,28]
Experiment details
Tissue used Whole
blood
Neutrophils PBMC PBMC PBMC PBMC PBMC Whole
blood
PBMC Whole
blood
Whole blood Whole blood
RNA extraction PAXGene Ambion Qiagen Ambion Qiagen Qiagen Qiagen PAXGene Qiagen Qiagen PAXGene PAXGene
Microarray platform Lab-
Arraytor
In-house Affymetrix Affymetrix Affymetrix Lab-
Arraytor
Affymetrix Affymetrix In-house Affymetrix Affymetrix Affymetrix
No. of genes or probe
sets
340 18,664 14,500 54,675 12,623 340 54,613 14,500 18,432 33,000 54,675 54,675
Signature genes
Sepsis vs. control 50 50 137 138 867 1,837 54 3,714 1,906 459
Survival vs. death 10 28
¶Signature genes were searched but not found.
RNA denotes ribonucleic acid. G-Pos/Neg denotes Gram-Positive sepsis or Gram-Negative sepsis. PBMC denotes peripheral blood mononuclear cells.
T
a
n
g
e
t
a
l
.
C
r
i
t
i
c
a
l
C
a
r
e
2
0
1
0
,
1
4
:
R
2
3
7
h
t
t
p
:
/
/
c
c
f
o
r
u
m
.
c
o
m
/
c
o
n
t
e
n
t
/
1
4
/
6
/
R
2
3
7
P
a
g
e
5
o
f
1
1purified leukocytes isolated from whole blood (for exam-
ple, neutrophils or mononuclear cells). Affymetrix was
the most common microarray platform used. In total,
gene-expression profiling of 784 individuals were per-
formed across four different microarray platforms.
Results on the assessment of the methodological qual-
ity of each microarray study are presented in Table 3.
Just over half of the studies fulfilled the MIAMI criteria
(Minimum Information About Microarray Experiment,
published guidelines on the design, conducting, analysis
and reporting of the microarray experiments) [7]. Only
seven studies performed internal validation of
microarray data and independently validated their
reported gene lists in separate data sets. Raw microarray
data are available in only 7 out of the 12 cohorts.
A wide range of statistical approaches were used by
the included studies. Table 3 provides detailed informa-
tion on the reporting of the statistical methods by each
study. Most studies provided details on the method used
for normalization. Normalization is a data processing
method that ensures only genes, which are truly differ-
entially expressed between phenotypes of interest, are
detected, instead of those caused by experimental arte-
facts or variation in the microarray hybirdization
Table 3 Methodological quality of microarray experiments
Prucha
[14]
Tang-
1
[15,16]
Ramilo
[17]
Tang-
2
[18]
Talwar
[8]
Payen
[19]
Cobb
[20,21]
Pachot
[22]
Prabhakar
[9]
Calvano
[10]
Wong
[23-26]
Johnson
[27,28]
Data acquisition
Tissue
homogeneity of
target samples
Low High High High High High High Low High Low Low High
Experiments follow
miame criteria
¶
Yes Yes Yes Yes Not
clear
Yes Not
clear
Not
clear
Not clear Not clear Yes Not clear
Reporting of
normalization
method
No Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes
Analytical issues
Method for gene
selection
t test t test Non-
parametric
test
t test ANOVA t test Multiple Not
clear
Not clear SAM ANOVA
and fold
change
Non-
parametric
test
Issue of variance
estimation
addressed
No Yes No Yes No No Not
clear
Not
clear
Not clear Yes No No
Comparison to
other diagnostic
markers
No No No No No NA Yes Yes No No No Yes
Correction for
multiple testing
Yes Yes Yes Yes Yes NA Yes Yes No Yes Yes Yes
Reporting of
classifier
performance
No Yes No Yes NA NA No Yes NA NA Yes NA
Reporting of
prediction accuracy
No Yes Yes Yes NA NA Yes Yes NA NA Yes NA
Validation of data
Cross validation of
signature genes
No Yes Yes Yes No No Yes Yes NA No Yes Yes
External validation
in independent
samples
No Yes Yes Yes No No Yes Yes NA Yes Yes No
Ratio of test/
training sample
size
NA 1.14 2.00 1.00 NA NA 0.50 0.23 NA 0.75 0.77 NA
Adjustment for
confounders
No Yes Yes No NA NA No No No NA Yes Yes
Raw data made
publicly available
No Yes Yes Yes Yes Yes No No No No Yes No
PCR validation Yes No Yes Yes Yes Yes Yes Yes Yes No No Yes
Minimum Information About Microarray Experiment checklist [7]. ANOVA denotes analysis of variance. SAM denotes Significance Analysis of Microarrays [29].
NA denotes not applicable.
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Page 6 of 11process. Different statistical approaches were used for
detecting statistically significant genes, depending on the
study design used in each cohort (Table 3). Multiple
testing corrections were used by most studies to
minimize a false positive rate in the significant genes
(Table 3). However, variance estimation was poorly
reported in most studies. A variety of variance estima-
tion techniques were used by the included studies;
but details were lacking in most studies (conventional
t-statistics based variance estimation methods under-
estimate the true variance of microarray data, so several
variance estimation methods for microarray data have
been developed). Overall, the reporting of statistical
methods was variable among studies.
Pathogen recognition
Sepsis activates pathogen recognition pathways in host
l e u k o c y t e s .T h i si se v i d e n tin most studies. Up-regula-
tion of pathogen recognition receptors, such as toll-like
receptors and CD14, was observed (Table 4). This was
accompanied by the activation of signal transduction
pathways, a process essential for subsequent transcrip-
tion of immune response genes. The signal transduction
pathways include nuclear factor kappa-B (NK-kb), mito-
gen activated protein kinase (MAPK), Janus kinase
(JAK) and transducer and activator of transcription pro-
tein (STAT) pathways (Table 4). The up-regulation of
both pathogen recognition and signal transduction path-
way genes was observed in most cohorts, including
experimental and clinical sepsis, paediatric and adult
patients, early and late sepsis.
Inflammatory response
In contrast to the above findings, changes in inflamma-
tory pathways were much less consistent. A distinctive
pro-inflammatory or anti-inflammatory phase, as
depicted in the classic sepsis model, was not seen during
any stage of sepsis. The early, transient rise in some
pro-inflammatory mediators was evident only in a
minority of studies (Table 5). In some studies, the
expression of anti-inflammatory genes dominated over
pro-inflammatory genes. In others, changes in inflam-
matory genes were noticeably absent. No studies
demonstrated a clear transition from a pro-inflammatory
phase to an anti-inflammatory phase during the course
of sepsis. Overall, the transcriptional changes in inflam-
mation-related genes are highly variable in most cohorts.
We next identified, in each cohort, genes that are well
known in the sepsis literature (for example, tumour
related factor (TNF), interleukin (IL)-1, IL-8, IL-10 and
TGF-beta). In particular, we were interested to see
whether there was any systematic difference in their
expression patterns between cohorts (for example, early
sepsis vs. late sepsis). We restricted our analysis to
cohorts of comparable microarray platforms (for exam-
ple, Affymetrix) and target tissues (for example, whole
blood). In this analysis, we found no consistent pattern
of gene expression in any of the well-established
markers of inflammation (pro-inflammatory or anti-
inflammatory). Further analyses by stratifying cohorts
based on patient groups (paediatric vs. adults) or pre-
sentation (pneumonia or non-specified sepsis) yielded
similarly negative findings.
Table 4 Gene-expression changes in pathogen recognition
Pathogen recognition Signal transduction
Johnson
[27,28]
Increase expression in toll-like receptor (TLR)
pathway genes.
Increased expression in pathways genes associated with NF-kB, STAT, JAK and
MAPKs.
Talwar [8] Increase expression in TLR pathway genes. Increased expression in genes associated with STAT, JAK and MAPKs
pathways.
Calvano [10] Increase expression in TLR pathway genes and CD14
genes.
Increased expression in genes associated with STAT, NF-kB, CREB, JAK and
MAPKs pathways.
Prabhakar [9] Increase expression in genes encoding for CD14
molecules.
Increased expression in genes associated with JAK pathway.
Prucha [14] Increased expression in genes associated with MAPKs pathway.
Tang-1
[15,16]
Reduced expression in pathways genes associated with NF-kB and MAPKs
pathways.
Tang-2 [18] Increase expression in TLR pathways genes. Increased expression in genes associated with JAK, STAT and MAPKs
pathways.
Cobb [20,21] Increased expression in genes associated with MAPKs pathway.
Wong [23-26] Increase expression in TLR pathways genes. Increased expression in genes associated with NF-kB STAT and MAPKs
pathways.
Payen [19] Increase expression in TLR pathways genes in
survivors.
Greater expression of genes associated with MAPKs pathway in non-survivors.
Pachot [22] Increase expression in TLR pathways genes in
survivors.
Greater expression of genes associated with MAPKs pathway in non-survivors.
Abbreviations; NF-ĸB denotes nuclear factor kappa-B, MAPKs denotes mitogen activated protein kinase, JAK denotes Janus Kinase, STAT denotes transducer and
activator of transcription protein, CREB denotes cAMP responsive element binding protein, TLR denotes toll-like receptor.
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Page 7 of 11Table 5 Gene-expression in inflammation and immunity
Timing Gene-expression Overall effect Changes in inflammatory and immune genes
Johnson
[27,28]
Pre-sepsis (12 to
36 hrs prior to
the diagnosis)
↑394 genes and
↓65 genes
Activation of host response to
infection.
Increased expression of genes associated with pro-
inflammatory cytokines (IL-1, IL-18), immune cell
receptor signalling (IFNR, IL-10RA, TNFSF) and T cell
differentiation (IFNGR, IL-18R, IL-4R).
Activation of counter-regulatory
mechanism that limits the pro-
inflammatory response.
Increased expression of genes that limit pro-
inflammatory cytokines (SOCS3).
Talwar [8] Early Sepsis (0 to
24 hrs)
↑439 genes and
↓428 genes
Activation of host response to
infection.
Increased expression of genes associated with cytokines
(IL-1R, CCR1, CCR2, IL-17) and S100 calgranulins
(S100A12, S100A11, S100A9, S100A8). Increased
expression of genes associated with arachidonate
metabolites (ALOX5) and anti-pathogen oxidases (CYBA,
SOD)
Activation of counter-regulatory
mechanism that limits the pro-
inflammatory response.
Increased expression of anti-inflammatory cytokines (IL-
1RA, IL-10R) and reduced expression of pro-
inflammatory genes (TNFSFR).
Repression of immune cells and
host defence, including antigen
presentation by phagocytes.
Reduced expression of genes associated with T cells,
cytotoxic lymphocytes and natural killer cells (T cell
receptor, CD86, IL-2 receptor, TNFRSF7, CD160,
cathepsin, CCR7, CXCR3, CD80). Reduced expression in
MHC class II genes.
Calvano
[10]
Early Sepsis (0 to
24 hrs)
↓ more than 1,857
(>50%)
¶
Activation of host response to
infection.
Increased expression of genes associated with pro-
inflammatory cytokines (TNF, IL-1, IL-1A, IL-1B, IL-8,
CXCL1, CXCL10).
Increased expression of genes associated with
superoxide-producing activities and cell-cell signalling.
Activation of counter-regulatory
mechanism that limits the pro-
inflammatory response.
Increased expression of genes that limit the
inflammatory response (SOSC3, IL1-RAP, IL1-R2, IL10 and
TNFRSF1A).
Repression of immune cells and
host defence, including antigen
presentation by phagocytes.
Reduced expression of genes associated with immune
response in lymphocytes (TNFRSF7, CD86, CD28, IL-7R,
lL-2RB).Reduced expression in MHC class II genes.
Prabhakar
[9]
Early Sepsis (0 to
24 hrs)
↑31 genes and ↓23
genes
Activation of host response to
infection.
Increased expression of pro-inflammatory genes (IL-1B,
TRAIL) and S100 calgranulins. Increased expression of
genes associated arachidonate metabolites (ALOX5,
SOD).
Activation of counter-regulatory
mechanism that limits the pro-
inflammatory response.
Increased expression of genes associated with cytokine
suppression (SOCS1, SOCS3).
Reduced antigen presentation by
phagocytes.
Reduced expression in MHC class II genes.
Prucha
[14]
Late-sepsis (1 to
5 days)
↑19 genes and ↓31
genes
Diminished pro-inflammatory
response.
Increase expression of pro-inflammatory genes (IL-18,
S100A8, S100A12), but reduced expression in others
(TNF, IL8RA, CASP5, IL-6ST).
Enhanced anti-inflammatory
response.
Increased expression of anti-inflammatory genes
(TGFb1).
Reduced lymphocyte function and
antigen presentation by
phagocytes.
Reduced expression of genes associated with
lymphocyte function (IL-16, CD69, CD8, CD36, CX3CR1).
Reduced expression in MHC class II genes.
Tang-1
[15,16]
Late-sepsis (1 to
5 days)
↑35 genes and ↓15
genes
Diminished pro-inflammatory
response.
Reduced expression of pro-inflammatory genes (TNF,
IL8RA, CASP5)
Reduced immune cell function. Reduced expression of genes that modulate immune
cell activation (IL-16, CD69, CD8, CD36).
Tang-2
[18]
Late-sepsis (1 to
5 days)
↑105 genes and
↓33 genes
Diminished pro-inflammatory
response.
Reduced expression of pro-inflammatory genes
(TNFSF8), S100 calgranulins S100A8) and IL-4 pathway.
Increased anti-inflammatory
response.
Increased expression of anti-inflammatory genes (IL-
10RB, TGFb1).
Reduced antigen presentation by
phagocytes.
Reduced expression in MHC class II genes.
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A major limitation of the above studies is that the find-
ings could be confounded by the variable time from
onset of sepsis (since the precise time of infection is
often unknown). We, therefore, performed a separate
analysis on studies that used an in vivo endotoxin chal-
lenge model. In these studies, endotoxin was injected
into healthy volunteers and blood sampling was per-
formed at regular intervals (up to 24 hours). Conse-
quently, the exact time of onset of infection is known
and the effect of timing on gene-expression changes can
be clearly defined. We found three endotoxin challenge
studies in our data set [8-10]. All three studies used
similar experimental protocols. The analysis showed that
endotoxin challenge elicited an activation of pathogen
recognition and signal transduction pathways, similar to
findings in other non-endotoxemia studies. However,
the findings on the inflammatory markers were
again conflicting. In one study, a predominantly anti-
inflammatory profile was observed [8]. In the other two
studies, a mixed profile (anti-inflammatory and pro-
inflammatory) was observed [9,10]. Hence, even after
allowing for the effect of timing, we still could not find
any discernible pattern in inflammation-related genes as
described in the classic sepsis model.
Discussion
Historically, cytokine studies suggested that there was a
linear transition from pro-inflammatory cytokines to
anti-inflammatory cytokines during the course of sepsis.
However, these patterns are infrequently seen in clinical
settings. In fact, only a few infections follow the classic
two-phase model (for example, meningococcal sepsis or
contaminated blood transfusions). Recently, studies have
shown that inflammatory cytokines in sepsis follow a
variable time course [2,3]. Our systematic review extends
this growing body of evidence by adding genome-wide
data from a variety of clinical settings. In our review, we
found that neither a distinctive pro/anti-inflammatory
phase nor a clear transition from a pro-inflammatory to
anti-inflammatory phase could be seen during sepsis. We
also did not observe any discernible pattern in the beha-
viour of well-established inflammatory markers (for
example, TNF-related genes) across the cohorts. Overall,
we did not find strong genomic evidence that supports
the classic two phase model of sepsis.
The negative finding of our review on the inflamma-
tion-related genes is unexpected, considering that the
other two well-studied biological phenomena in sepsis,
namely the activation of pathogen recognition (for
example, toll-like receptors) and signal transduction
pathways, are confirmed in most cohorts. The negative
finding on inflammation related genes remained even
after the cohorts were stratified by timing, patient
groups or clinical settings.
The lack of clinical evidence to support the classical
two-phase model has been known to many clinicians.
The temporal relationship of an early pro-inflammatory
Table 5 Gene-expression in inflammation and immunity (Continued)
Wong
[23-26]
Late-sepsis (1 to
5 days)
↑862 gene and
↓1,283 genes (Day
1)
Activation of both pro-
inflammatory and anti-inflammatory
response.
Increased expression of both pro-inflammatory (IL-1 and
IL-6) and anti-inflammatory (IL-10, TGFb1) genes.
Increased expression of genes associated with receptor
signalling and granulocyte colony stimulating factor.
↑1,072 gene and
↓1,432 genes (Day
3)
Repression of immune cells and
host defence, including antigen
presentation by phagocytes.
Reduced expression of genes associated with antigen
presentation, immune cell activation, IL-8 and IL-4
pathways.
Reduced expression in MHC class II genes.
Cobb
[20,21]
Late sepsis (1 to
5 days)
1,837 genes Unclear as only a small subset of
genes are available for analysis.
Increased expression of pro-inflammatory genes (IL-
1beta, NAIP, CEACAM8, and the alpha-defensins).
Payen [19] Recovery (>5
days)
↑1 gene and ↓3
genes (survivors).
Ongoing immuno-suppression
throughout the 28-day study
period.
In survivors, there was a progressive reduction in the
expression of genes associated with S100 calgranulins
(S100A8 and S100A12) and T cell activation (IL-3RA).
↑29 gene and ↓7
genes (non-
survivors).
Greater extent of immuno-
suppression in non-survivors.
In non-survivors, there was an even greater reduction in
the expression of genes associated with immune cell
activation (CXCL14, CD180, CD244, CCR6 and CD84). In
the same patients, there was also an increase expression
of apoptosis genes (PPARG, DAP3 and HBXIP) and anti-
inflammatory genes (PAFAH1B1 and IL-4R).
Survival is accompanied with
recovery of some immune
functions.
Recovery of MHC class II gene (CD74) in survivors
occurs on day 28.
Pachot
[22]
Recovery (>5
days)
↑18 genes
(survivors) and ↑10
genes (non-
survivors)
Survival in sepsis is associated with
restoration of immune function.
In survivors, there was an increased expression of genes
in modulating T cell activation and receptor signalling
(ILRB2, CXC31, TRDD3, TIAM1, FYN).
↑ denotes increased gene-expression compared to controls; ↓ denotes reduced gene-expression compared to controls.
¶Exact number not given by the author.
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Page 9 of 11phase followed by an anti-inflammatory phase, as
depicted in the classical model, is rarely seen in clinical
settings. However, this model remains the reigning para-
digm under which many anti-sepsis drugs are being
developed. The data outlined above therefore provide
molecular evidence to validate the increasing concern
among clinicians that the current inflammation-based
definition of sepsis is too simplistic to describe a com-
plex syndrome [11-13].
While we did not find evidence to support the inflam-
mation-based model of sepsis, we are not able to rule
out the existence of other evidence that may support
such a model. This is because of the limitations of our
study. For example, our review has excluded other gene-
expression studies that did not use microarray platform.
As a result, our review is based on data from one parti-
cular methodology. Studies using other experimental
approaches may repudiate/strengthen our findings.
Furthermore, the observed gene-expression changes are
restricted to circulating leukocytes. The changes in resi-
dent leukocytes in local tissue are likely to be very dif-
ferent from circulating leukocytes. Additional data from
resident cells will provide a more complete understand-
ing of the host response to sepsis. Another limitation is
that our review does not provide information on
changes occurring on a proteomic level, as they are not
within the scope of this review. Lastly, most studies did
not provide information on the leukocyte differential in
the blood sample. The variability in leukocyte differen-
tials could have confounded our findings. Given these
several limitations, our findings need to be interpreted
with caution. A more thorough evaluation of the sepsis
model should involve integrating data from other
experimental approaches, including in vitro studies, ani-
mal models and proteomic data.
Our review also revealed several significant methodo-
logical limitations of the current microarray studies in
sepsis. First, many of the studies included in our
review did not make their raw data publicly available.
This makes it difficult for other researchers to verify
their findings or to undertake meta-analysis. In addi-
tion, each study uses different statistical analysis
approaches. In particular, different variance estimation
methods were used by studies. However, most studies
have adequate sample size; hence the impact of var-
iance estimation on our findings is likely to be mini-
mal. Another notable problem is that authors of each
paper present their findings differently, making com-
parison or generalization of their data difficult. For
example, some studies reported only a subset of the
discovered genes, while others report functional ana-
lyses findings without actually listing the discovered
genes. To better utilize the findings derived from gene-
expression studies of sepsis, a uniform standard of
reporting published microarray findings, such as those
required for cancer studies [6], should be considered
by all study authors in the future.
Conclusions
Our systematic review shows that sepsis-related inflam-
matory changes are highly variable on a transcriptional
level. The arbitrary distinction of separating sepsis into
pro-inflammatory and anti-inflammatory phases is not
supported by gene-expression data.
Key messages
￿ Sepsis-related inflammatory changes are highly
variable on a transcriptional level.
￿ These changes are not consistent with the estab-
lished model of sepsis, where a biphasic pro-inflam-
matory and anti-inflammatory process is thought to
underpin the host response.
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